The James Altucher Show
Description
Dr. David Sinclair returns to discuss ER-100, the first partial epigenetic-reprogramming therapy to enter human clinical trials. He explains how three Yamanaka factors restored visual function in animal studies, why the first trial targets optic-nerve diseases, and what this could mean for treating other diseases associated with aging.